The Library
Protective effect of recombinant human glucagon-like peptide-1 (rhGLP-1) pretreatment in STZ-induced diabetic mice
Tools
Tools
Tools
Wu, Ye-Lin, Huang, Jing, Liu, Jian, Jin, Ming-Fei, Gu, Mei, Hong, Yiguo and Wu, Zi-Rong (2011) Protective effect of recombinant human glucagon-like peptide-1 (rhGLP-1) pretreatment in STZ-induced diabetic mice. Journal of Peptide Science, Vol.17 (No.7). pp. 499-504. doi:10.1002/psc.1352
Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1002/psc.1352
Abstract
Human glucagon-like peptide-1 (hGLP-1) and its mimetics have emerged as therapies for type 2 diabetes. However, clinical treatment of diabetes with hGLP-1 is ineffective because of rapid DPPIV-mediated hGLP-1 degradation in the circulation. In this study, we investigated the protective effect of recombinant human glucagon-like peptide-1 (rhGLP-1) treatment on STZ-induced diabeticmice. Mice were treated daily with rhGLP-1 (24 nmol/kg body weight) starting before or after STZ injection (40mg/kg body weight) to induce diabetes. Mice pretreated with rhGLP-1 before but not after STZ showed significantly reduced blood glucose levels (P < 0.05), increased oral glucose tolerance (area under the curve, 1740 +/- 71.18 vs 2416 +/- 205.6, P < 0.05). Furthermore, the bioproduct of lipid peroxidation, MDA, was reduced and SOD and GSH-PX activities were enhanced globally and in pancreas of mice that received rhGLP-1 pretreatment before STZ, when comparing with STZ-treated mice. Finally, STZ-induced pancreatic islet damage was rescued by rhGLP-1 pretreatment. Taken together, the results of this study demonstrate that rhGLP-1 pretreatment has a protective effect against STZ-induced diabetes in mice. These findings suggest that the GLP-1 pretreatment may be a new therapeutic strategy in the preventive and protective treatment during diabetes initiation and progression. Copyright (C) 2011 European Peptide Society and John Wiley & Sons, Ltd.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RB Pathology R Medicine > RC Internal medicine |
||||
| Divisions: | Faculty of Science > Life Sciences (2010- ) > Warwick HRI (2004-2010) Faculty of Medicine > Warwick Medical School |
||||
| Library of Congress Subject Headings (LCSH): | Streptozotocin, Oxidative stress, Diabetes, Non-insulin-dependent diabetes, Glucagon-like peptide 1 | ||||
| Journal or Publication Title: | Journal of Peptide Science | ||||
| Publisher: | John Wiley & Sons Ltd. | ||||
| ISSN: | 10752617 | ||||
| Official Date: | July 2011 | ||||
| Dates: |
|
||||
| Volume: | Vol.17 | ||||
| Number: | No.7 | ||||
| Page Range: | pp. 499-504 | ||||
| DOI: | 10.1002/psc.1352 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Funder: | National New Drug Development Program of China | ||||
| Grant number: | 2009ZX09102-253 (NNDDPC) |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
